Xemed collaborator Isabel Dregely has been selected by the International Society of Magnetic Resonance in Medicine as the recipient of their W.S. Mooore Young Investigator Award.

Xemed has learned that the International Society of Magnetic Resonance in Medicine selected Isabel Dregely, a Xemed collaborator who completed her PhD in the University of New Hampshire’s Department of Physics last December 2010, as the recipient of their W.S.Moore Young Investigator Award. Three finalists competed by presenting talks in a plenary session and by defending a poster on their work to the awards committee. The selection process was completed on Thursday May 12 at this year’s annual meeting in Montreal, Canada, and the award was presented by Dr. Li Debiao, President of the Society.

The subject of Dr. Dregely’s research was “Hyperpolarized Xenon-129 Gas-Exchange Imaging of Lung Microstructure: Preliminary Results in Subjects with Obstructive Lung Disease”. She used magnetic resonance imaging to map out in three-dimensions the rate of uptake of gases within the lungs, and determine the density of gas exchange tissues as well as the thickness of these tissues in healthy volunteers and patients with lung disease. Professor Bill Hersman of UNH and Xemed directed her research project, which included collaborators from Xemed, the University of Virginia School of Medicine, and the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital. This work could be important for upcoming clinical trials of new lung medicines or for personalized care and management of patients.

Figure 1. Kai Ruppert (UVa), Isabel Dregely (UNH), and Bill Hersman (UNH and Xemed) at the ISMRM Young Investigator Award ceremony

Figure 2. Dr. Dregely’s work included the development of a xenon-tuned chest coil with 32 radiofrequency receive elements to detect the imaging signals from MagniXene™

ABOUT XEMED—We are a product-focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gases, partnering with clinical researchers and the pharmaceutical industry to advance pulmonary functional MRI through regulatory approval towards worldwide commercial availability.

At Xemed, our mission is to develop inhaled diagnostic agents that are capable of improving the standard of care of respiratory diseases. We will accomplish this by establishing hyperpolarized gas as a scientifically robust, clinically validated, FDA approved, and publically available diagnostic agent for magnetic resonance imaging of lung functional microstructure. We work to demonstrate effectiveness in two fields: 1) guiding clinical management of respiratory diseases, and 2) as a drug development tool to evaluate of the safety and efficacy of new therapies